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“There is a lot of hard work that needs to be done” 
Martti Ahtisaari 
  
  
i 
Abstract 
Nanoparticles have emerged as one of the most promising tools for addressing 
central challenges in cancer diagnostics and therapy. This thesis presents the design, 
surface functionalization, biocompatibility, intracellular interactions and 
applicability of nanoparticles as potential tools for cancer diagnosis and RNAi 
therapeutics. The thesis is divided into two parts; 1) cancer cell imaging and 2) siRNA 
delivery.  
In part 1, studies were performed with inherently fluorescent carbon-based 
nanoparticles (nanodiamonds, NDs, and nanographene oxide, nGO) in order to 
evaluate their suitability for cancer cell imaging (in vivo and in vitro). A novel 
application of NDs in super resolution correlative light and electron microscopy is 
presented here, whereby NDs are used as a dual-purpose fluorescent and electron 
dense probes for correlative multi-modal microscopy. Further, the intracellular 
interactions of NDs are studied to understand the biocompatibility of non-
degradable NDs and the reasons underlying the biocompatibility. 
Moreover, this thesis elucidates the role of organic surface modifications for 
enhancing the optical properties of nanographene oxide (nGO) for in vivo imaging. 
When nGO was surface functionalized with the organic polymer PEG-PEI 
(polyethyleneimine – a polyethylene glycol co-polymer), and attached to the cancer 
cell affinity ligand FA (folic acid), its dispersibility, cellular internalization and 
quantum efficiency were improved compared to the non-modified nGO. The surface 
functionalized nGOs were further applied as optical markers for the non-invasive in 
vivo imaging of cancer cells in a model organism. The nGOs were found to be well 
suited for detecting cancer cells over the studied 1-week period. 
In part 2, systems for the efficient delivery of therapeutic cargo to cancer cells were 
studied using a nanodiamond (ND) - silica (MSN) composite (ND@MSN) and 
mesoporous silica nanoparticles (MSN) with redox responsive linkers.  ND@MSN, 
a novel composite material was synthesized by taking advantage of the properties of 
both the ND (photoluminescence) and the MSN (drug-delivery). The validation of 
ND@MSN for drug delivery was performed by surface functionalizing the composite 
particles with the co-polymer PEG-PEI and by loading the ND@MSN with a 
hydrophobic luminescent dye, which acted as a model drug. The intracellular 
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delivery of a hydrophobic drugs is generally challenging, but the ND@MSN surface 
functionalized with co-polymers (Cop) demonstrated excellent efficiency for the 
intracellular delivery of the hydrophobic model drug. Other noteworthy features 
related to the use of ND@MSN-Cop were that no premature extracellular release of 
the dye was observed, that the endosomal escape and intracellular release of the cargo 
were achieved and that the subsequent tracking of the NDs in the cell was possible. 
For the delivery of siRNAs into cancer cells, the MSN nanocarriers were synthesized, 
in attempt to overcome challenges associated with the in vivo delivery of siRNA. 
Hyperbranched PEI and redox-responsive intracellular triggerable bonds were thus 
incorporated into the developed MSN nanocarriers. The design of the MSN 
nanocarriers took into consideration important aspects of in vivo delivery, such as 
the high loading of siRNA, intracellular cleavable linkers, high cellular uptake, and a 
large pore size to host the siRNA molecules and to protect them from degradation. 
In the experimental set-up, the MSN nanocarriers demonstrated the sustained 
intracellular release of the siRNA (120h), while offering protection from enzymatic 
degradation. The gene knockdown efficiency was further evaluated using a 
transfection control siRNA. The MSN nanocarriers performed remarkably well and 
showed excellent transfection efficiency. 
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Sammanfattning 
Nanopartiklar utgör lovande verktyg för att ta itu med centrala utmaningar inom 
cancerdiagnostik och terapi. Denna avhandling presenterar design, 
ytfunktionalisering, biokompatibilitet, intracellulära växelverkningar och 
tillämplighet av nanopartiklar som potentiella verktyg för cancerdiagnos och RNAi-
terapi. Avhandlingen är uppdelad i två delar: 1) cancercellsavbildning och 2) tillförsel 
av siRNA. 
I del 1 genomfördes studier med naturligt fluorescerande kolbaserade nanopartiklar 
(nanodiamanter, ND och nanografenoxid, nGO) för att utvärdera deras lämplighet 
för cancercellsavbildning (in vivo och in vitro). En ny tillämpning av ND i 
superupplöst, korrelativ ljus- och elektronmikroskopi presenteras här, varigenom 
ND används som ett fluorescerande och elektron-tätt avbidningsmedel med 
dubbelfunktion för korrelativ multimodal mikroskopi. Vidare studeras de 
intracellulära växelverkningarna hos ND för att förstå biokompatibiliteten hos dessa 
icke-nedbrytbara ND och orsakerna bakom den observerade biokompatibiliteten. 
Vidare belyser denna avhandling rollen hos organiska ytmodifieringar för att 
förbättra de optiska egenskaperna hos nanografenoxid (nGO) för in vivo avbildning. 
När nGO ytfunktionaliserades med den organiska polymeren PEG-PEI 
(polyetylenimin-polyetylenglykol sampolymer) vilken var vidare kopplad till 
cancercellaffinitetsliganden FA (folsyra), förbättrades dess dispergerbarhet, 
cellupptag och optiska egenskaper jämfört med icke-modifierad nGO. De 
ytfunktionaliserade nGO partiklarna användes vidare som optiska markörer för 
icke-invasiv in vivo avbildning av cancerceller i en modellorganism. nGO partiklarna 
befanns vara väl lämpade för att detektera cancerceller under den studerade perioden 
på en vecka. 
I del 2 studerades läkemedelsadministrationssystem för effektiv transport av 
terapeutiska molekyler till cancerceller genom användning av ett nanodiamant (ND) 
-kiseldioxid (MSN) -kompositmaterial (ND@MSN) och mesoporösa kiseldioxid 
nanopartiklar (MSN) med redox-responsiva länkare. Det nya ND@MSN 
kompositmaterialet syntetiserades för att utnyttja egenskaperna hos både ND 
(fotoluminescens) och MSN (läkemedelstillförsel). Utvärderingen av ND@MSN för 
läkemedelsadministration utfördes genom ytfunktionalisering av partiklarna med 
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den ovan nämnda sampolymeren (PEG-PEI) och genom att ND@MSN partiklarna 
laddades med ett hydrofobt luminescerande färgämne, vilket fungerade som ett 
modellläkemedel. Den intracellulära tillförseln av ett hydrofobt läkemedel är i 
allmänhet utmanande, men ND@MSN-partikelytan funktionaliserad med 
sampolymer (Cop) uppvisade utmärkt effektivitet för intracellulär tillförsel av det 
hydrofoba modellläkemedlet. Andra anmärkningsvärda egenskaper relaterade till 
användningen av ND@MSN-Cop var att ingen prematur extracellulär frisättning av 
färgämnet observerades, intracellulär frisättning av de aktiva molekylerna 
uppnåddes och att den efterföljande spårningen av ND i cellen var möjlig. 
För tillförsel av siRNA till cancerceller syntetiserades MSN bärarpartiklar i försök att 
övervinna de utmaningar som är förknippade med in vivo administrering av siRNA. 
Hyperförgrenad PEI och redox-responsiva intracellulärt klyvbara bindningar 
införlivades således i dessa nyutvecklade MSN bärarpartiklarna. Utformningen av 
MSN bärarpartiklar tog hänsyn till viktiga aspekter för in vivo administrering, såsom 
hög laddningsgrad av siRNA, intracellulärt klyvbara länkare, högt cellupptag och en 
stor porstorlek som kan inhysa siRNA-molekylerna samt skydda dem mot 
nedbrytning. I den experimentella uppställningen demonstrerade MSN 
bärarpartiklarna fördröjd intracellulär frisättning av siRNA (120h) samtidigt som 
skydd mot enzymatisk nedbrytning tillhandahölls. MSN bärarpartiklarna fungerade 
anmärkningsvärt bra och uppvisade utmärkt transfektionseffektivitet. 
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1 
1 Introduction 
Nanotechnology is an interdisciplinary field that includes the synthesis, design, and 
application of nanomaterials1. In the last several decades, biomedical 
nanotechnology has focused primarily on the development of drug-delivery systems 
and diagnostic probes2–5.  The most notable examples of nanotechnology in cancer 
research include the targeted delivery of anti-cancer drugs6–8, nanosized contrast 
agents for magnetic resonance imaging9–11, liposomes for breast cancer 
therapeutics12–14, and the highly specific detection of DNA and proteins15,16. 
Nanotechnology is recognized as one of the leading technologies for making 
significant advances in cancer theranostics (diagnostics and therapy)2,3. The 
physiochemical properties of nanomaterials significantly differ from the bulk 
materials. Nanotechnology allows tuning the shape, size, and surface properties of 
nanomaterials for the loading of therapeutic or imaging agents with high stability, 
while maintaining compatibility with biological fluids17. The nanoscale-sized 
nanomaterials allow a larger surface area for loading of the therapeutic agents as well 
as interactions with biomolecules at the same scale. For example, mesoporous silica 
nanoparticles (MSNs) are porous, surface modifiable, biodegradable materials, 
which offer a large surface to volume ratio18–20. The large surface area can be used to 
load therapeutic agents via non-covalent physical adsorption or by covalent bonding.  
Applications of nanotechnology in cancer treatment have the potential for the 
selective administration of therapeutic molecules to target organs with minimal side 
effects. Nanotherapeutics are growing at a steady rate in clinical and research 
applications21,22. A few commercially approved nanopharmaceuticals for the 
treatment cancer already exist. Notable commercially available nanopharmaceutical 
products include Doxil®, Myocet®, Eligard®, and Opaxio® 23. The translation of results 
obtained from biomedical research into clinical applications and successful 
commercial products is a long and risky path. However, there is considerable 
optimism that nanoparticles would provide a theranostics approach for treating 
cancer.  
Molecular heterogeneity24,25 and drug resistance26–28 present daunting challenges for 
the treatment of cancer. Cancerous cells show a molecular heterogeneity between the 
primary and metastatic tumors29–32 as well as resistance towards chemotherapy26,28. 
The multitude of heterogeneity among cancer phenotypes can allow a sub-
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population of cancerous cells to circumvent monotherapy31. New targeted therapies, 
based on personalized medicine can offer an approach to treating cancer  in a way 
that takes into account the genetic profiles of tumors in individual patients33,34. Since 
traditional chemotherapeutic treatments might respond differently to the individual 
genetic makeup of patients, these new approaches are expected to provide solutions 
for the complex challenges in cancer treatment 
One of the latest approaches for treating cancer is based on the therapeutic delivery 
of a siRNA (small interfering RNA)35. siRNAs are 21-25 nucleotides long, naturally 
evolved molecules with roles in essential cellular responses36. A siRNA causes the 
selective silencing and degradation of a target mRNA37. A siRNA based approach 
could allow the specific degradation of oncogene mRNAs, which are involved in the 
molecular pathways that drive cells into malignancy.  Recent therapeutic 
applications have demonstrated the potential of using siRNAs for treating different 
types of cancers such as HER2-positive breast cancer38. RNAi (RNA interference) has 
the potential to overcome present challenges that cancer treatment faces, such as 
drug resistance38,39. siRNA therapy has shown the potential for overcoming drug 
resistance in a study with the breast cancer drug, trastuzumab38. However, the 
applications of siRNA in cancer therapy have been restricted mainly to in vitro 
studies, due to the unavailability of efficient platforms for in vivo delivery40,41. RNAi 
therapeutics requires in vivo delivery vehicles that provide high bioavailability, a high 
loading degree, targeted delivery to tumors and protection of the siRNAs for 
sustained targeted release42,43. NPs could be ideal delivery vehicles for siRNA for 
applications in in vivo tumor targeting. NPs based platforms offer the potential for 
overcoming challenges posed by the current in vivo delivery vehicles42,44–46. NPs have 
several characteristics that qualify them as one of the preferred siRNA delivery 
vehicles for in vivo cancer therapeutics. The characteristics and their significance for 
siRNA delivery systems are discussed in the following chapters.  
Nanomedicine could provide an integrated platform for diagnosing, targeting drug-
delivery and monitoring the therapeutic response in cancer treatment. Combining 
diagnostic imaging with therapy could enable the development of responses to 
challenges posed by cancer treatment. Multimodal, non-invasive, high-resolution 
imaging is emerging as a powerful tool for providing cellular/molecular information 
for applications in cancer diagnostics47–51. The targeted delivery of imaging agents 
can be achieved by the conjugation of molecules that recognize specific cell surface 
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markers 52–54. The targeted delivery of contrast agents can be used for whole tumor 
mapping. Nanoparticles can be used as contrast agents with fluorescence 
microscopy55–58 and magnetic resonance imaging (MRI)9,11. Inherently fluorescent or 
fluorophore conjugated nanoparticles are currently being studied for applications in 
different bioimaging techniques. Bioimaging with fluorescent nanoparticles can be 
used in three different techniques. 1) microscopic detection of cells with internalized 
fluorescent nanoparticles59,60; 2) targeted bioimaging of specific cells or cellular 
structures using antibodies, ligands or oligomers attached to nanoparticles for 
specific recognition52,54; 3) nanoparticles can be used as chemical sensors for imaging 
disease-related changes in the distribution of chemical species such as pH, calcium, 
oxygen etc61. 
  
4 
2 Review of the Literature 
2.1 Optical probes for cell imaging 
Fluorescence microscopy is rapidly evolving with the technical improvements to 
imaging instruments, imaging probes and imaging methods62–68. Over the years, the 
technological advancements have focused on the development of improved contrast 
agents, new kinds of instruments, and higher resolution imaging64.  
 
Figure 1. Schematic representation of the principle of fluorescence emission and confocal 
microscopy. a) Fluorophores can be excited with a single photon of a suitable shorter 
wavelength. The fluorophore absorbs the energy and enters the excited state. In the excited 
state, the fluorophore releases energy in the form of heat and vibration. It relaxes to the 
ground state by emitting a longer wavelength. b) Fluorophores can be excited by the process 
of two-photon excitation, where two photons of a longer wavelength are used to provide 
sufficient energy for excitation and the fluorophore emits a shorter wavelength. c) The 
principle of confocal microscopy is based on the application of confocal pinholes that 
selectively collect the in-focus light from the specimen’s focal plane and point by point 
illumination of the sample. 
One of the most commonly used fluorescence-based cell imaging techniques is 
confocal microscopy. Confocal microscopy is a laser scanning based microscopy 
method that is compatible with fixed and live cell imaging. Confocal microscopy is 
based on two principal ideas: 1) rejection of out of focus light by utilizing confocal 
pinholes and 2) point by point specimen illumination69. The optical resolution 
offered by a confocal microscope is limited by the diffraction of light and its spatial 
resolution, approximately 250-300nm.  
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Two-photon microscopy is a commonly used fluorescence microscopy technique, 
based on nonlinear interactions between light and a fluorophore70–72. The 
fluorescence generated by a two-photon process depends on the absorption of two 
photons simultaneously by the same molecule. These photons have longer 
wavelengths, mostly infra-red wavelengths, each of these photons carries one-half of 
the excitation energy71. Since the wavelength and the energy of photons are inversely 
proportional, the wavelength of these two photons is theoretically 2X times longer 
than the single-photon excitation wavelength. The major application of using two-
photon excitation microscopy is for in vivo imaging72. Using a longer excitation 
wavelength allows deeper penetration into animal or thick tissues compared to 
single-photon microscopy. Two-photon excitation microscopy has other advantages 
such as less photobleaching, low auto-fluorescence, no requirement of pinholes for 
the collection of in-focus light compared to  single photon microscopy73. 
In last decade, the development of super resolution fluorescence microscopes has 
circumvented the resolution limit of light by utilizing novel methods such as STED 
(Stimulated emission depletion) 74–76, SIM (Structure-illuminated microscopy)77,78, 
PALM (Photoactivated localization microscopy)79,80 and other similar super 
resolution techniques81. Among them, STED was the first super resolution technique 
to break the barrier of the diffraction limit of light and it was based on the de-
excitation of fluorophores using stimulated emission depletion75. STED techniques 
have been demonstrated for the imaging of fixed as well as live cells82–85. STED 
techniques could achieve a superior resolution (X-Y) up to 6-30nm76,83. The 
advancement in resolving nanoscale objects with fluorescent microscopes has played 
a vital role in the understanding of the precise localization of molecules within cells.  
Fluorescence imaging requires fluorophores for microscopic visualization. 
Thousands of organic fluorophores have been devised to provide labels for biological 
systems. The large spectral range of organic fluorophores can be applied at the 
cellular and sub-cellular level and specific labeling at the molecular level. The 
development of intrinsic fluorescent proteins has allowed biologist to genetically tag 
a protein of interest in living organisms or individual cells86. The most commonly 
used fluorescent proteins belong to the green fluorescent protein (GFP) family. 
There are multiple derivatives of GFP, such as red fluorescent proteins (RFP), yellow 
fluorescent protein (YFP), which offer a wide selection in the visible range (400-700 
nm).  The desirable characteristics of fluorophores include 1) a specific excitation 
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wavelength; 2) detectability with fluorescence microscopy; 3) a high molar 
absorption coefficient, bright with a high quantum yield; 4) solubility in relevant cell 
media; 5) photostablity87 and 6) properties that allow it to be used as a tag or mean 
that it can be genetically expressed within the target cells, or both.  
Organic fluorophores and fluorescent proteins are compatible with advanced 
imaging techniques such as laser scanning confocal microscopy, two-photon 
microscopy88 and superresolution fluorescence techniques89,90. Practically, a 
fluorophore can be recycled from the ground state to the excited state infinite times, 
but fades by a phenomenon known as photobleaching87. The bleaching of the 
fluorophore is a generic term for all associated processes that contribute to the loss 
of the fluorescent signal. In case of organic fluorophores and fluorescent proteins, 
bleaching can occur at the molecular level in several different ways87. In general, 
bleaching of the fluorophore is mainly associated with triplet states. Long-lived 
triplet states of fluorophores have a higher probability of interacting with molecular 
oxygen. Singlet oxygen or any reductive species can interact with fluorophores and 
covalently alter the activity of the fluorophores91. The process of bleaching is a major 
problem with organic fluorophores and fluorescent proteins.  
2.2 Nanoparticles as bioimaging probes 
To overcome current existing shortcomings associated with fluorophores, NPs could 
be a powerful tool for labeling cells in disease diagnostics49,92–94. NPs offer advantages 
over traditional fluorophores for targeted imaging57,95,96. NPs can be tuned with 
proper surface functionalization to attach specific molecules for the targeted imaging 
of cancer cells, with the added advantage of being fluorescently detectable. Targeted 
bioimaging can be performed with the attachment of cancer cell targeting ligands97,98, 
oligomers99, or antibodies to the surface of the nanoparticle 52. Typically, NPs 
conjugated or labeled with an organic fluorophore, as well as inherently fluorescent 
NPs have shown to be virtually inert, with little interaction with cellular proteins100. 
Moreover, they have generally demonstrated distinctly better photostability in 
comparison to their free-dye counterparts101,102. 
Multiple types of NPs are used for bioimaging, including nanoparticles derived from 
silica19,103, quantum dots57, gold nanoparticles104, fluorescent carbon nanoparticles105, 
upconversion nanomaterials106,107, and lanthanide materials108,109. C-dots (carbon 
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dots), a carbon based imaging nanoprobe, has entered human trials for its potential 
applications110. Silica-based nanoparticles (SNs) were the first nanoparticle to be 
applied for bioimaging applications100. SNs are inherently non-fluorescent, however, 
imaging agents can be incorporated into them by either physical adsorption or 
chemical conjugation. MSNs have been used in cell imaging and molecular 
sensing111. Silica nanoparticles (SNs) are most commonly used due to their high 
loading capacity of fluorescent dyes 100. SNs can be surface conjugated with 
lanthanide luminescent chelates such as europium, terbium, and gadolinium112–114. 
SNs have shown low cytotoxicity and efficient cell imaging capabilities115.  
Inherently fluorescent NPs also exist. These include quantum dots, carbon dots, 
nanodiamonds, single and multi-walled carbon nanotubes,55,57,116–118 upconverting 
NPs106 and lanthanide doped NPs114. Fluorescent NPs have in general shown good 
contrast and good photostability, and their sizes are on the nanometer scale, which 
facilitates their internalization into cells100. These NPs have shown different degrees 
of toxicity toward cells. One popular example is the application of quantum dots 
(QDs) for cell imaging. QDs exhibit high photostability and size dependent emission 
over the entire visible wavelength57. QDs can be readily internalized by the cells, 
however, their clearance from tissues can be challenging. Moreover, QDs have 
shown to interact with the thiol groups of cysteine in the cellular proteins and can 
exhibit toxic effects due to the leakage of heavy metals in cells100.  
Table 1. List of commonly used inherently fluorescent nanomaterials for bioimaging. 
Nanomaterial Material source 
Quantum Dots Semiconductor metals (Zn, Cd, Se) 
Carbon Dots Carbon 
Nanodiamonds Carbon 
Nanographene Oxide Carbon 
UCNPs NaYF4 (Doped with Er(III), Yb(III) or Tm(III)) 
 
Among the fluorescent nanoparticles, carbon based inherently fluorescent NPs can 
be used as promising substitutes for overcoming the toxic effects of semiconductor 
quantum dots119,120. Fluorescent carbon nanoparticles such as nanodiamonds (NDs), 
carbon dots, nanographene oxide (nGO), fullerenes, and carbon nanotubes are being 
explored for their potential applications in bioimaging due to their unique optical 
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nature and high biocompatibility121 -the major component of these materials being 
carbon, a non-toxic “element of life”. 
Fluorescent carbon nanomaterials can be synthesized by different methods. For an 
example, NDs can be synthesized by detonation based methods on a commercial 
scale117. Another such example of chemical synthesis is the synthesis of 
nanographene oxide by the oxidation of micro or nanographite by a 3:1 ratio of a 
mixture of sulfuric to nitric acid 122.  
NDs and nGOs have shown to be non-toxic and stable optical markers for 
bioimaging60,123. They possess unique optical properties well suited for bioimaging 
applications. In case of NDs, the fluorescence originates from defects in the crystal 
lattice of diamonds. NDs have more than 500 optical centers. Among them, 
negatively charged nitrogen vacancies (NV-) are the most studied due to their 
photostability65,124,125. 
 
Figure 2. Schematic representation of a photostable nitrogen-vacancy center. In the 
diamond lattice, a nitrogen atom (N) is substituted by carbon (C), adjacent to a vacant 
space (V)126.  
NDs can be typically excited at 480- 532 nm and the emission wavelength of NDs 
lies in the red range (650-800 nm)55,60,76. The emission in the red range is well-suited 
for deep tissue imaging. NDs are well-suited for different multi-modal microscopy 
applications such as live cell imaging, super resolution STED imaging76 and multi-
photon microscopy. Additionally, the electron dense nature of NDs can be used 
for visualization with electron microscopy60. The unique optical and electron dense 
properties of NDs are well-suited for further applications through method 
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development for correlative microscopy, where there is a growing need for unique 
landmarks that can be detected with both optical and electron microscopes127,128. 
Nanographene oxide (nGO) also belongs to the family of fluorescent carbon 
nanomaterials 95,122,123. They have unique optical properties comparative to those 
exhibited by the QDs. nGOs have demonstrated excitation dependent emissions, 
which can be detected throughout the visible spectrum. nGO nanoparticles have 
generally shown to be biocompatible with cells120 and they have demonstrated only 
weak interactions with cellular proteins129. nGOs have been applied to cell, tissue, 
and small animal imaging130 and one reported paper suggested that they can 
efficiently internalize and are mainly localized within the cytoplasmic space131. NDs 
and nGOs can be surface functionalized with organic polymers for enhanced cellular 
uptake, better colloidal stability, prevention of aggregation and could influence their 
optical properties60,123.  
2.3 Surface functionalization of nanoparticles 
Surface functionalization of NPs is a commonly used strategy for reducing 
interactions with the immune system115,132,133. Surface functionalization of NPs 
influences their cellular internalization, intracellular delivery, specific cell 
recognition, nanoparticle stability and endosomal escape of cargo133–136. The basic 
design of surface functionalization can be varied according to the nature of the 
application. In case of cancer nanomedicine, the general strategy used for surface 
functionalization includes the attachment of affinity ligands98,137 or antibodies53 for 
the recognition of cancer cells, polymeric coating for enhanced cellular 
uptake115,134,138,139 or the endosomal escape of a drug or siRNA140,141, and the 
conjugation or surface doping of imaging agents60,114.  
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Figure 3. Schematic depiction of nanoparticle surface modifications for applications in 
cancer nanomedicine. Nanoparticles can be surface functionalized with the PEI-PEG 
polymer (positively charged + colloidally stable). Attachment of cell surface recognizing 
peptides, antibodies, ligands etc. Imaging agents can be either chemically conjugated or 
physically adsorbed.   
NPs have been surface functionalized with a wide variety of surface recognition 
molecules (peptides142,143, antibodies144, or ligands145–147). The attachment of surface 
recognition molecules (active targeting) improves the differential affinity toward 
specific proteins being present on the cell surface. Commonly used receptors for 
cancer cell targeting include folate receptors148,149, transferrin receptors150,151, and 
lectin receptors152,153 etc. For example, folate receptors (FR) are overexpressed in a 
majority of cancer cells97,148. Cancers known to overexpress folate receptors include 
breast, lung, kidney, ovarian and brain tumors. The surface functionalization of NPs 
with folic acid (the ligand for FR) may thus enhance their specific cellular uptake into 
tumor cells. 
The targeted cellular uptake of ligand attached NPs (active targeting154,155) can be 
further enhanced by surface coating the NPs with polymers (passive targeting156). 
Surface functionalization with polymers contributes to the stability of the NPs and 
enhances passive targeting. NPs have generally demonstrated preferential 
extravasation into the leaky tumor vasculature as compared to healthy tissues. NPs 
thereby remain localized due to an enhanced permeability and retention (EPR) effect 
(passive targeting) 2,157,158.  An example is this is coating NPs with PEG (polyethylene 
glycol). PEG coating enhances the circulation time of the NPs and prevents the 
adsorption of blood serum proteins with low toxicity159–161. In order to facilitate 
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cellular uptake, NPs can be coated with a combination of polymers along with 
PEG123,134,139. One such additional coating can be performed with the PEI 
(polyethyleneimine) polymer. PEIs are synthetic cationic polymers that provide a 
high positive charge on the NP surface132,133. The positive charge on the NP surface 
influences cellular uptake, endosomal escape162,163 and enhances the loading of DNA 
and the delivery of siRNA for the gene therapy of cancer cells164.  
 
Figure 4. Schematic representation of interactions between NPs bearing positive and 
negative charges with the negatively charged lipid bilayer. NPs coated with apositively 
charged functional group (PEI) show high affinity or cell membranes. Instead, the 
negatively charged NPs have demonstrated a lower affinity for interactions with the cell 
membrane. 
Knowledge about interactions between NPs and the lipid bilayer of the cell 
membrane is critical when designing applications such as imaging, phototherapy, 
and gene therapy132,133,165. The presence of positively charged groups, such as PEI play 
a crucial role in NPs interactions with the lipid bilayer of the cell membrane, and can 
maximize cellular uptake132,133. It has been demonstrated that NPs bearing a negative 
or neutral surface charge are less-well adsorbed on the cell membrane than are 
positively charged NPs. These non-positively charged NPs shows less cellular 
internalization in comparison to the NPs with a positive surface charge.  
2.4 siRNA nanomedicine therapy for cancer 
RNA interference (RNAi) is an evolutionarily conserved mechanism for the 
regulation of endogenous pathways by selectively inhibiting the expression of 
mRNA36,166. The specific silencing by double-stranded RNAs was first observed by 
Fire and Mellow in Caenorhabditis elegans37. Later, the specific mechanism was 
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described in plant and mammalian cells40. The application of synthetic siRNA for 
mRNA silencing and mechanism of RNAi was described by Elbashir et al,36,166. In 
mammalian cells, siRNAs are synthesized from double-stranded exogenous RNA, 
processed by the enzymatic activity of a ribonuclease enzyme, Dicer166. Dicer belongs 
to the family of RNAse III enzymes and produces small interfering RNA molecules, 
with the lengths of 21-25 nucleotides. siRNAs are produced by Dicer enzymes form 
a RISC (RNA induced silencing complex) with Argonaute (Ago) proteins. At RISC, 
the guide strand is selected for mRNA recognition, whereas the other strand is 
degraded167.  
The properties of the RNAi pathway can be exploited for the selective regulation of 
genes of interest. The RNAi pathway could be a potent way developing future 
therapeutics for the downregulation of oncogenes involved in cancer. RNAi based 
cancer therapeutics requires delivery vehicles for the efficient transportation of 
siRNAs to the target cancer cells. In general, siRNAs are prone to degradation by the 
enzymatic activity of RNAses168,169.  
 
Figure 5. Schematic representation of MSNs as vectors for siRNA delivery. siRNA can be 
efficiently delivered to cells via organic surface functionalization, and stimuli responsive 
siRNA release can be achieved by including intracellular redox cleavable linker groups to 
the MSN.  
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Despite the presence of numerous vectors for siRNA delivery, most commercial 
systems have shown efficient delivery only in vitro. Moreover, these are not 
commonly applied for the in vivo tumor-targeted delivery of siRNAs. The other 
concerns with siRNA delivery rise mostly from the nature of the siRNA molecules, 
such as their low bioavailability, high polarity and poor stability under physiological 
conditions. Therefore, the design of delivery vehicles should offer consideration to 
these challenges posed by siRNAs. An efficient in vivo system should address issues 
such as siRNA protection, systematic sustained release, and high loading capacity. 
Several formulations have been applied to achieve the systemic delivery of siRNAs 
such as viral vectors170, polymers164,171, cationic lipids172 and inorganic NPs138,173,174. 
Among the above-mentioned approaches, MSN can be utilized for designing a 
rational delivery system based on the unique characteristics of MSNs175–177. They have 
several characteristics that qualify them as preferred siRNA delivery vehicles for in 
vivo cancer therapeutics. The low cytotoxicity and high cellular uptake of MSNs have 
been well characterized over the past decade177–179. MSNs are synthetically versatile 
porous materials with an ordered pore structure resulting in a high surface area and 
large pore volume180. These structural characteristics of MSNs can be exploited for 
reaching a high loading capacity for siRNAs, while the localization of the siRNAs in 
the pores consequently offers efficient protection from degradation173,175. The 
applicability of MSNs can be tuned for the delivery of siRNAs. For example, 
modifications in material design would include MSNs with expandable pores for the 
incorporation siRNAs175,181. Stimuli responsive siRNA release from the mesopores of 
MSNs can be achieved by the inclusion of intracellular redox cleavable linker groups 
and tethering with hyperbranched poly(ethyleneimine) (PEI)175. PEI is a well-
recognized organic polymer employed in gene delivery applications135,163. PEI has 
highly positively charged secondary and tertiary amine groups.   Under physiological 
conditions, such as during entrapment in acidic endosomal vesicles, PEI can be 
protonated in the acidic environment.  This leads to the endosomal escape of cargo 
by the rupture of the endosomes vesicle, which is known as the proton sponge 
effect162. In general, MSNs can be efficiently surface functionalized for the targeted 
in vivo delivery of siRNAs. MSNs can be further conjugated with organic 
fluorophores to allow their subsequent imaging and detection.  
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3 Aims of the study 
The overall aim of the thesis is to study in detail the multimodal imaging and 
intracellular trafficking of novel imaging probes and drug/siRNA delivery 
vehicles. 
The specific objectives are: 
1. Evaluation of surface functionalized fluorescent probes (NDs and nGO) for 
cancer cell imaging (Paper I&IV).  
2. Investigation of the intracellular trafficking of nanodiamonds and their 
application as dual probes for correlative light-electron microscopy (Paper 
II&III). 
3. Evaluation of silica coated and surface functionalized NDs as single multi-
functional nanoprobes for bioimaging and drug-delivery in cancer cells 
(Paper I).  
4. Development and evaluation of redox responsive MSN nanocarriers for 
intracellular siRNA delivery into cancer cells (Paper V&VI).  
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4 Materials and methods 
In this section, a short summary of the methods used in the study is given. A detailed 
description of the phenomena studied and techniques used can be found in the 
original publications. 
Table 2. List of applied techniques for investigating the corresponding phenomena. 
Phenomenon studied Technique used Publication 
No 
Particle morphology TEM, AFM I,IV 
Spectral characterization of inherently 
photoluminescent nanomaterials 
Spectrophotometry I,IV 
Cytotoxicity assays WST-1, Crystal violet 
staining 
I,IV-V 
Cellular uptake of nanomaterials Confocal microscopy I,IV-V 
Cell imaging of nanomaterials Confocal microscopy I-II, III-V 
Intracellular trafficking of NDs Confocal microscopy, TEM II 
In vivo imaging of nGO Two-photon microscopy IV 
In vivo imaging of MSN Two-photon microscopy VI 
NDs as correlative intracellular probe 
for STED and TEM 
STED, TEM III 
Intracellular drug delivery capacity by 
ND-SiO2 
Confocal microscopy I 
siRNA delivery by MSN Live cell microscopy, 
IncuCyte imaging 
V 
4.1 Morphology and optical characterization of nanodiamonds and 
nanographene oxide 
Nanoparticle size was studied with TEM (Paper I&IV) and AFM (Paper IV)60,123. 
Photoluminescence (PL) spectra were studied with a spectrophotometer. The PL 
spectrum of NDs (Paper I) was recorded at 488 nm with a LABRAM HR800 
spectrophotometer (HORIBA Instruments, Japan) at room temperature. The PL 
spectra and quantum yield of nGOs (Paper IV) was recorded with a PTI Quanta-
Master spectrofluorimeter (Photon Technology International, USA). The excitation 
sources were 488 nm (argon laser), diode lasers at 405 nm and 532 nm. The emission 
was recorded in the range of 410-800 nm. 
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4.2 Cell Studies 
Cell studies were performed with HeLa cells (Paper I), MDA-MB-231 cells (Paper II-
V) and A549 cells (Paper IV). Cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, 2mM L-glutamine, 
and 1% penicillin–streptomycin (v/v). The cells were maintained at 37°C, 5% CO2. 
4.2.1 Cell viability assay 
The cell viability assessment of nanomaterials was performed with the WST-1 assay 
(Paper I, IV-V). WST-1 is a ready-to-use cell viability reagent (Roche Diagnostics, 
Germany). 10,000 cells per well were added to a 96 well plate containing cell media 
DMEM and incubated overnight to allow them to adhere to the surface. Cell media 
containing nanomaterials was added to cells. After, 48-72h, 10 μl of WST-1 was added 
to each well and left to incubate for 3h at 37°C, 5% CO2. The absorbance values for 
each sample were read at 430 nm by Tecan Ultra microplate reader (MTX Lab Systems, 
Inc.). The observed absorbance value was correlated with the number of viable cells in 
the presence of positive (toxin) and negative control cells (without nanoparticles).  
4.2.2 Cellular uptake and cell imaging 
Cellular uptake and cell imaging (fixed cells) measurements were performed with a 
TCS SP5 confocal microscope (Leica microsystems, Germany).  The excitation 
source was an argon laser at 488 nm for NDs, nGO and MSNs (Paper I-II, IV-V). 
The emission from nGO, MSNs (FITC) and NDs was collected in the range of 500-
550 nm and 650-730 nm. The image acquisition included the LASAF software (Leica 
application suite), PMT (Photo multiplier tube) and 100X oil objectives (NA 1.45). 
4.2.3 In vivo imaging (CAM model) 
The chick embryo chorioallantoic membrane (CAM) as was used as an in vivo animal 
model for imaging implanted tumors (Paper IV). The CAM model serves as an easy-
to-image, fast and inexpensive model for performing short-term in vivo 
experiments182. The CAM model was used to image nGO labeled tumors (Paper IV). 
For cellular applications, nGO nanoparticles were surface coated with PEG 
(polyethylene glycol) –PEI (polyethyleneimine) polymers (Cop) and the cancer cell 
affinity ligand, folic acid (FA) was attached to them. The cancer cells (MDA-MB-231, 
HeLa, and A549) were labeled with nGO-Cop-FA and further, mixed with BD 
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Matrigel (BD Biosciences, USA) and implanted over the CAM. The tumor was allowed 
to grow over the CAM for 1 week. The in vivo imaging of the nGO labeled tumors was 
performed with two-photon microscopy70,73. The instrumental setup consisted of TCS 
SP5 MP (Multi-photon, Leica microsystems) with a 20X water dipping objective, Non-
descanned detectors (NDD). A Ti-sapphire femtosecond pulse laser at 800 nm was 
used as the excitation source for nGO-Cop-FA. The emission from nGO-Cop-FA 
labeled tumors was collected using NDD detectors at 430-480nm. 
4.2.4 Intracellular trafficking and investigation of the cellular toxicity of NDs 
Intracellular trafficking of NDs was studied with confocal microscopy (2-48h) using 
early endosomal and lysosomal markers (Paper II). For the intracellular trafficking 
study, non-functionalized NDs were used to study cellular fate. NDs have been 
reported to be internalized into a cell by clathrin-mediated endocytosis119. EEA1 
(early endosomal antigen-1) was used as a specific marker for ND internalization in 
fixed cells. 1 ̊ anti- EEA1 antibody (ThermoFisher Scientific Inc, USA) was used for 
marking early endosomes. The localization of NDs and their interactions with 
lysosomes were studied for 2-48h. LysoTracker Green® (ThermoFisher Scientific Inc, 
USA) was used as a marker for lysosomes in live cells.  
4.2.5 TEM studies of intracellular trafficking 
TEM studies were performed with ND internalized MDA-MB-231 cells for (24-120h). 
Cells were fixed at each respective time point. A routine cell sample preparation protocol 
for TEM was followed. Cells were fixed with 5% glutaraldehyde in s-collidine buffer and 
postfixed with 2% OsO4 containing 3% potassium ferrocyanide, followed by successive 
steps of dehydration with ethanol and flat embedding using the 45359 Fluka Epoxy 
Embedding Medium kit. Thin sections of approximately 100 nm were prepared and 
stained with heavy metals (uranyl acetate and lead citrate). TEM microscopy was 
performed with an 80 kV JEOL JEM-1400 Plus (Joel Ltd, Japan).  
4.3 Evaluation of NDs as a correlative microscopy probe 
NDs are electron dense (TEM detectable) and photostable optical markers for 
fluorescence microscopy56,76. We evaluated the performance of NDs as nanosized 
dual markers for correlative microscopy. NDs were incubated with MDA-MB-231 
cells for 24h. ND internalized cells were processed for TEM imaging following 
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routine sample preparation. Thin 100 nm sections were placed over marker EM 
grids. After TEM imaging, the cell section was placed over glass over coverslip and 
mounted over glass slide for imaging. The TEM imaged section was imaged with a 
TCS SP5 STED microscope (Leica microsystems, Germany).  The NDs were excited 
with a 532 nm pulsed laser and PL was depleted with a STED beam at 765 nm. The 
emission was collected with an avalanche photo diode (APD) detector at the 665-705 
nm range. Further, the SuperTomo software was applied for the automatic 
correlation of TEM and STED images183.  
4.5 siRNA delivery by MSN 
4.5.1 Slow and sustained release of siRNA  
The slow and sustained release of siRNA from the mesoporous of MSN nanocarriers 
was observed with live cell confocal microscopy (Paper V). Alexa 555 fluorescently 
labeled siRNA (BLOCK-iT™ Alexa Fluor® Red Fluorescent Control, Life 
Technologies, US) was loaded in FITC conjugated-MSN nanocarriers. The 
intracellular release of siRNA was observed in MDA-MB-231 cells for 96h. siRNA 
release in live cells was measured with TCS SP5 (Leica microsystems, Germany). The 
MSN nanocarriers (FITC conjugated) were excited with a 488 nm argon laser and 
the Alexa 555 labeled siRNA was excited with a 561 nm HeNe diode laser. The 
emission from thre MSN nanocarriers and the siRNA was collected at 510-540 nm 
and 570-610 nm, respectively. A co-localization study of the MSN and siRNA signals 
was performed with the Volocity® 3D Image Analysis Software (Perkin Elmer). 
4.5.2 siRNA transfection efficiency 
The transfection efficiency of the MSN nanocarrier’s  was evaluated with the WST-1 
cell viability assay, colony growth monitoring by IncuCyte and a colony growth assay 
(Paper V)175. The transfection and gene knockdown efficiencies were evaluated with 
the commercially available AllStars Hs Cell Death Control siRNA (Qiagen, 
Germany). A 50 nM concentration of the AllStars Hs Cell Death Control siRNA was 
added to the MSN nanocarrier samples and the equivalent of AllStars Hs Cell Death 
Control siRNA was transfected with Lipofectamine® RNAiMAX (Invitrogen, 
Thermo Scientific, MA, USA). The transfection efficiency of the MSN nanocarriers 
was evaluated in comparison to Lipofectamine® RNAiMAX as a positive control.  
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5 Summary of the results 
The nanoparticles studied in this thesis are summarized in Table 3.  
Table 3. List of nanomaterials used in this study with surface functionalization and their 
respective studied applications. 
Nanomaterials Surface 
functionalization 
Application Publication 
No 
I) Cancer cell imaging  
Nanodiamonds 
(NDs) 
PEG, PEI In vitro imaging I 
Nanodiamonds 
(NDs) 
 Intracellular trafficking, 
correlative microscopy 
II-III 
Nanographene oxide 
(nGO) 
PEG, PEI, FA In vitro and In vivo 
imaging 
IV 
Mesoporous silica 
nanoparticles (MSN) 
PEG, PEI, FA In vivo imaging VI 
II) Drug/siRNA delivery  
Nanodiamonds-silica 
composite 
(ND@MSN) 
PEG, PEI Drug delivery I 
Mesoporous silica 
nanoparticles (MSN) 
PEI-Linker-PEI siRNA delivery V 
 
The results of the cell imaging and drug/siRNA delivery applications are presented 
in two separate sections I) Cancer cell imaging and II) Drug/siRNA delivery 
applications. 
I) Cancer cell imaging: Inherently fluorescent carbon nanoparticles (NDs and nGO) 
were evaluated for their suitability for in vitro (fixed cell) imaging (Paper I & IV). We 
studied the intracellular trafficking and cellular fate of NDs (Paper II). Further, NDs 
were used as dual probes for correlative light-electron microscopy (Paper III). nGOs 
and fluorescently labeled MSNs were evaluated for their feasibility for in vivo 
imaging using the chicken CAM model (Paper IV&VI).  
II) Drug/siRNA delivery applications: For therapeutic delivery applications, we 
developed a potential multifunctional material with photoluminescent NDs (core) 
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and MSN as a shell, for the delivery of a hydrophobic model drug and its subsequent 
detection in cells20. The composite material (ND@MSN) was surface functionalized 
with PEI-PEG polymers and the cancer cell affinity ligand folic acid (FA) was 
attached to it (Paper I). Further, we synthesized and evaluated the suitability of MSN 
nanocarriers for the long-term (120h) delivery of siRNAs into cancer cells (Paper V). 
For this purpose, MSNs were designed by the integration of hyperbranched PEI and 
redox-responsive linker arms for the stimuli-responsive intracellular long-term 
sustained release of the siRNAs into the cancer cells.  
5.1 Cancer cell imaging I 
5.1.1 Inherently fluorescent nanodiamonds 
The nanodiamonds used are photoluminescent (PL) and photostable markers 
suitable for cell imaging184. They have photostable and negatively charged PL 
nitrogen vacancies56 in their lattice. However, the optical properties of the NDs are 
dependent on the type of synthesis and successful creation of negatively charged 
nitrogen vacancies185. ND production lacks a universal quality control procedure and 
quality might vary from batch to batch. Therefore, it’s important to perform quality 
control tests for different batches of NDs. The NDs used in our evaluations were 
obtained from Tomei Diamond Co., Ltd (Japan) (Paper I). They were further 
irradiated with 2 MeV electrons to create nitrogen-vacancies. Irradiation of the NDs 
was performed as part of a collaboration at the General Physics Institute, Russian 
Academy of Sciences (Moscow, Russia) (Paper I).  
We studied the morphology, size distribution, cytocompatibility and the potential of 
NDs for in-vitro cell imaging (Paper I).  TEM was used to characterize their size and 
morphology. In general, NDs were typically below 100 nm in size. However, some 
NDs were smaller in size, roughly 30-40 nm (Figure. 6a). TEM studies suggested that 
the NDs were irregular in shape. A cell viability assay was performed with the 
nanodiamonds, as a prerequisite assessment for biological applications. Cells treated 
with nanodiamonds (10 μg/ml) showed comparable viability to control cells (Figure. 
6b). We used a known cell toxin (Calyculin A) as a positive control for toxicity.  In 
our experiments, NDs appeared non-toxic and the comparative cell viability can be 
seen in Figure 6b. We concluded that NDs were safe for further cell imaging 
application under our experimental conditions.  
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Figure 6. Nanodiamonds as photoluminescent probes for cellular imaging. a) 
Morphological and size characterization by TEM. b) Cytocompatibility assessment for ND 
and ND composites. Error bars represent standard deviation c) Cellular imaging of NDs in 
reflection mode. d) NDs as optical markers for cellular imaging. The PL signal from the 
NDs (red) can be seen localized to the cytoplasmic space of GFP expressing MDA-MB-231 
cells (green).  
Nanodiamonds were evaluated for their cellular imaging capabilities by confocal 
microscopy. We exploited both the refractive and PL properties of NDs. NDs have a 
high refractive index, and can be used for instance as optical markers for differential 
contrast microscopy. The scattered signals were bright enough to be distinguished 
from cellular autofluorescence (Figure. 6c). However, optimal imaging settings are 
required for image acquisition in the reflection mode. Intracellular NDs were imaged 
with confocal microscopy in the fluorescence mode using an excitation wavelength 
of 488 nm and emission was collected at 650-730 nm. The PL from NDs (red) is an 
efficient optical probe for cellular imaging (Figure. 6d). Moreover, NDs were seen 
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to be localized in the cytoplasmic space and mostly in aggregates. The aggregated 
nature of the NDs suggests their endosomal confinement in the cells. However, 
further investigations were performed to understand the intracellular trafficking of 
NDs (Paper II).  
5.1.2 Intracellular trafficking of nanodiamonds and investigation of cellular 
toxicity 
Investigating the cellular interaction and fate of NDs could offer important insights 
into the material’s biocompatibility. Despite the proven biocompatibility and 
efficient cellular internalization of NDs60,119,184,186,187, diamonds are recognized as one 
of the hardest known non-biodegradable materials, and  could thereby be toxic to 
cells. Clathrin-mediated endocytosis has been reported as the route of ND 
internalization into cells119. In a classical endocytotic process, the extracellular 
content moves primarily from early endosomes, mid-endosomes to late endosomes, 
and finally, vesicles merge with lysosomes as part of the degradation pathway188. 
Therefore, we investigated the localization of NDs with early endosomes and their 
interactions with lysosomes as a pre-state for exocytosis (Paper II).  
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Figure 7. Continuous endocytosis and exocytosis of NDs can be interpreted from intracellular 
trafficking events. Investigation of NDs localized in early endosomes, as markers for cellular 
uptake. a) After a 2h incubation NDs (red) are localized within early endosomes (green), and 
in the cytoplasm. b) After 6 h, large aggregates of NDs were seen localized with early 
endosomes. While another ND population was observed to form smaller aggregates and can 
be seen more dispersed in cells. c) After 24 h, three distinct populations of NDs can be observed 
in cells:  1) Early endosomal localized NDs, 2) NDs mostly aggregated but they were not 
localized within early endosomes and 3) a dispersed, distinct ND population, which was 
mainly localized in close vicinity of the plasma membrane (arrow). d) After 48 h, the 
observation suggests that a small but significant population of NDs can be seen localized 
within early endosomes. The larger population of NDs was not localized within early 
endosomes but can be seen dispersed in proximity of the plasma membrane (arrow).  
Temporal regulation of NDs in cells by lysosomes. e) After 2h of internalization, NDs (red) 
can be seen localized outside lysosomes (green). f) After 6 h, a population of NDs (red) was 
observed to be co-localized with lysosomes (green). Another population seems to be 
aggregated, but not localized within lysosomes and some lysosomes are seen without any 
NDs. g) After 24 h, the observation suggests that one population of NDs was mainly 
aggregated and co-localized with lysosomes, while another distinct, dispersed ND population 
was observed mainly located at the edges of the plasma membrane. h) After 48 h, the 
observation suggested that there was progressive co-localization of NDs (red) with lysosomes 
(green). However, a distinct and dispersed population of NDs was consistently observed to be 
localized in proximity of the plasma membrane (arrow).  
Nanodiamonds were observed after a 2h incubation to be internalized and localized 
within early endosomes (Figure. 7a). NDs were seen to localize in early endosomes 
forming large aggregates after 6 h of internalization. The size of the vesicular 
aggregates was approximately 1.5-2 μm as was observed by fluorescence microscopy.  
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Another ND population was observed not to be in early endosomes, and was mostly 
in the form of smaller aggregates and localized in a more dispersed fashion in the 
cytoplasmic space (Figure. 7b). After 24 h of internalization, we observed three 
distinct populations of NDs: NDs mainly co-localized with early endosomes, NDs 
aggregated but not localized with early endosomes and a spread-out, distinct 
population of NDs, which were mostly localized in the vicinity of the plasma 
membrane (arrow) (Figure. 7c). The size of early endosomes localized ND 
aggregates were comparable to that observed at 6h and 24h time points.   
After 48 h of ND internalization, a small yet significant population of NDs was 
associated with early endosomes, while a larger population of NDs was not bound to 
early endosomes but remained either aggregated or dispersed in the proximity of the 
plasma membrane (arrow) (Figure. 7d). Investigation of the localization of NDs 
with early endosomes over 48h revealed the presence of different ND population in 
cells. Further, interactions between NDs and lysosomes were studied to understand 
the subsequent fate of the NDs.  
We further investigated ND localization with lysosomes using the live cell 
LysoTracker dye. NDs were mostly localized outside lysosomes 2h after 
internalization and there was no observed co-localization of NDs with lysosomes 
(Figure. 7e). ND internalization after 6h showed a population of NDs co-localized 
with lysosomes. At the same time, there were other ND populations, which were also 
mostly confined but not co-localized with lysosomes. There was also the presence of 
lysosomes without any NDs (Figure. 7f). The observation at 24h suggests that one 
population of NDs was mainly confined and seen to be co-localized with lysosomes, 
while another ND population in the same cells was distinct, mostly dispersely located 
largely in proximity of the plasma membrane (Figure. 7g).  
Progressive co-localization of NDs with lysosomes was observed at 48h. Another 
notable observation was the presence of NDs in the cytoplasmic space, but not bound 
to lysosomes. However, a significant population of NDs was localized again in 
proximity of the plasma membrane (Figure. 7h). The co-localization of NDs with 
lysosomes and early endosomes suggests that one significant population of NDs was 
either localized with early endosomes or lysosomes at the 6h, 24h, and 48h time 
points, while another significant ND population was mostly localized in proximity 
of the plasma membrane. These observations suggest that the localization of NDs 
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with early endosomes (2h, 6h, 24h, and 48h) can be interpreted as the continuous 
endocytosis of NDs in cells (Figure. 7a-d).  
However, continuous endocytosis of NDs and in the absence of exocytosis would 
finally lead to the accumulation of NDs in cells. This would certainly cause adverse 
effects on cell proliferation, growth and thus contribute to cellular toxicity. However, 
we have also observed, and it has been also reported, that NDs can act as a non-toxic 
nanomaterial in cellular studies. Similarity, considering the localization of NDs with 
lysosomes (2h, 6h, 24h and 48h), the observations at different time points suggest 
some degree of co-localization at each given time point.  Therefore, it would be 
logical to hypothesize that the exocytosis and endocytosis of NDs occur 
simultaneously in cells. Cells could be using this endocytosis/exocytosis machinery 
to basically avoid the toxic effects of non-degradable NDs (Paper II).  
Evidence of exocytosis was provided by NDs internalized into eGFP expressing 
MDA-MB-231 cells. ND containing eGFP MDA-MB-231 cells were co-cultured with 
other cancerous line (HeLa, non-GFP MDA-MB-231) and a non-cancerous cells 
lines (HSF, MEF).  
 
Figure 8. Demonstration of ND exocytosis from cells. eGFP MDA-MB-231 cells grown in 
the presence of NDs show exocytosis, and exocytosed NDs were internalized by cells in the 
co-culture. a) HeLa. b) HSF. c) non-GFP MDA-MB-231 and d) MEF cells.  
eGFP expressing MDA-MB-231 cells were first cultured with NDs for 6 h to facilitate 
ND uptake. The culture medium was then changed to one not containing NDs, and 
HeLa, non-GFP MDA-MB-231, HSF or MEF cells were seeded into the co-culture. 
After 48h of co-culturing a significant ND population was seen in the co-cultured cells 
(Figure. 8), suggesting the exocytosis of NDs from the eGFP MDA-MB-231 cells.  
Furthermore, transmission electron microscopy was applied to visualize the sub-
cellular localization of NDs and to observe vesicle bound and peripheral ND 
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populations. Earlier fluorescence microscopy experiments had showed the presence 
of different NDs populations in cells at various time points: either vesicle bound NDs 
(early endosomal and lysosomal) or NDs localized in the proximity of the plasma 
membrane. TEM imaging confirmed (Figure.  9a-b) that the localization of the NDs 
was mostly in a vesicular space (green arrow); as well as in proximity of the plasma 
membrane (orange arrow). The observation at 48h (Figure. 9c-d) suggests the 
progressive aggregation of NDs, mostly in a vesicular space. The observed vesicles 
were seen to be mostly packed with NDs and the sizes of the ND aggregates in the 
vesicles were approximately1-2 μm as seen by TEM (Figure. 9c-d).  
 
Figure 9. TEM imaging suggests vesicular localized NDs and NDs localized in the proximity 
of the plasma membrane. a-b) TEM imaging of NDs at 24h, suggest NDs localized in 
vesicles (green arrow) as well as in close proximity of the cell membrane (orange arrow). c-
d) Vesicular aggregated NDs observed in cells at 48h. e) At 72h, TEM imaging shows an 
ND packed vesicle, which might be exocytosed from cells f) while NDs are confined in the 
vesicular space. Furthermore, vesicular aggregation was observed (g-h) at 96h. i) vesicular 
aggregated and j) NDs in the proximity of the cell membrane at 120h. k-l) empty vesicle 
seen in control cells. 
It was observed (72h) that a NDs packed vesicle might be exocytosed from the cell 
(Figure. 9e). The ND packed vesicle was confined on the edge of the plasma membrane 
(Figure. 9e). However, other ND containing vesicles remained aggregated at 72h 
(Figure. 9f).  There were similar observations of NDs localized in a vesicular space at 
96h and 120h (Figure. 9g-j). TEM observations also concluded that NDs were not 
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localized in nuclei, mitochondria or Golgi. Vesicular localized NDs were aggregated 
and distinct from the empty vesicles of control cells (Figure. 9k-l).  
TEM imaging revealed two distinct ND populations: one confined in a vesicular 
space, and the other mostly in the proximity of the plasma membrane. Taken 
together with the fluorescence microscopy study, the experimental observations 
suggest that substantial populations of cellular NDs were confined within early 
endosomes and lysosomes (6h, 24h, and 48h). These observations imply that cells 
could be managing the intracellular amount of NDs by continuous endocytosis and 
exocytosis. This could be a possible mechanism for cells to overcome the toxic effects 
of non-degradable NDs (Paper II).  
5.1.3 NDs as a correlative STED-TEM microscopy probe 
There is an evident need for a single fluorescent and electron dense probe for 
correlative light and electron microscopy (CLEM)189. Dual-contrast landmarks are 
required to match the details in the multi-modal images. CLEM allows combining 
the advantages of light and electron microscopy190,191. Fluorescence microscopy can 
be employed to study specific details in live or fixed cells. Subsequently, cells can be 
fixed and further studied with TEM. TEM allows the study of the ultrastructural 
details of cells at high-resolution. However, there is a resolution gap between TEM 
and fluorescence microscopy. In recent decades, with the development of super-
resolution fluorescence nanoscopy methods, the resolution mismatch has been 
alleviated but not completely removed. The technology used here, Stimulated 
Emission Depletion (STED),  is a super-resolution fluorescence microscopy 
technique, based on point-scanning confocal microscopy75. 
NDs, as mentioned above, are made of an inherently fluorescent, photostable and 
electron dense material56,60,185,187, and NDs are compatible with the STED technique. 
NDs have been used as stable probes that can be efficiently resolved by STED 
microscopy down to 6 nm76,85. The electron dense nature of NDs allows them to be 
detected also by TEM (Figure 6a). Therefore, NDs were applied as a dual contrast 
probe for STED-TEM correlative microscopy (Paper III). 
Preparing cells samples for TEM involves harsh treatments with chemical fixatives 
such as Glutaraldehyde, 2% OsO4 containing 3% potassium ferrocyanide and it also 
requires heavy metal staining to allow detection with the electron microscopy 
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(uranyl acetate and lead citrate). As a result of the severe chemical treatments, 
traditional organic fluorophores do not survive and hence cannot be further detected 
by fluorescence microscopy. However, NDs remained fluorescent even after the 
strong chemical fixation and heavy metal staining used in TEM sample preparation 
(Figure. 10a-c). As can be seen in (Figure. 10d-f), TEM processing does not appear 
to harm the fluorescent properties of the NDs and they can be subsequently imaged 
with fluorescence microscopy (Figure. 10d-f).  
 
Figure 10. Nanodiamonds as dual contrast probes for STED-TEM correlative microscopy. 
a-c) TEM imaging of a cell with 4 distinct endosomal localizations of NDs. d) STED 
imaging of intracellular nanodiamonds. e) Confocal imaging of NDs localized at spot 1. f) 
STED depletion improves the overall resolution and precise localization of NDs in cells at 
spot 1. g-h) Correlative STED-TEM of the cell using nanodiamonds as an intracellular 
probe for both modalities.  
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Further, STED depletion could be used to resolve the NDs at optical super-resolution 
(Figure. 10f); where the resolution was evaluated from the distance of two NDs to 
be < 100nm. SuperTomo was used to correlate the multi-modal images183(Figure. 
10g-h). The NDs enable the precise mapping of the high-resolution structural details 
shown in TEM, with the fluorescence image obtained with STED (Figure. 10g-h).  
NDs did not display photobleaching in our experiments, and they provided a strong 
intrinsic contrast in CLEM (Paper III).  This is an additional advantage of NDs, to 
their previously shown potential applications for cellular imaging. 
5.1.4 Nanographene oxides as inherently fluorescent carbon probes 
Nanographene oxides (nGO) are a type of carbon based nanostructures192. nGOs 
have tuneable PL properties that are attractive for cell imaging, e.g. low toxicity and 
stable PL192,193. The nGO used in our study was synthesized by oxidizing micro- and 
/or nanographite in a 3:1 ratio of sulfuric to nitric acid (SNOx) (Paper IV)122.  
 
Figure 11. Investigation of the size distribution of nGOs by transmission electron 
microscopy (TEM) and atomic force microscopy (AFM). a) TEM imaging of nGOs. b) 
Atomic force microscopy of nGOs. nGO nanoparticles. 
TEM and AFM were applied to study the size distribution of nGOs. The nGO 
particles were mostly below 10 nm in size. (Figure. 11a). We further applied AFM 
to investigate the size distribution of the nGOs. AFM data showed a similar of size 
distribution (Figure. 11b). 
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Table 4. Nanographene oxide (nGO) particles used in the study with surface 
functionalization. 
Nanographene oxide 
nanoparticles 
Applied surface functionalization 
nGO Uncoated 
nGO-Cop Coated with PEG-PEI (Cop) 
nGO-Cop-FA Coated with PEG-PEI (Cop) and attached with 
affinity ligand FA (Folic acid). 
 
The optical properties of nGO, nGO-Cop and nGO-Cop-FA were characterized with 
spectrofluorimetry. nGO (coated and uncoated) has shown excitation-dependent 
emission over the entire visible spectrum (Paper IV). Multiple optical centers were 
observed with nGOs and emission maxima were observed at approximately 70-90 
nm from the excitation wavelength123. A comparative spectrofluorometric analysis 
of nGO, nGO-Cop, nGO-Cop-FA nanoparticles was performed by exciting at 405 
nm, 488 nm and 532 nm (Figure. 12a-c).  
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Figure 12. Surface functionalization of an nGO improves its photoluminescent properties. 
The observation of excitation-dependent emission spectra of nGOs (coated and uncoated) 
nanoparticles. a) nGO (uncoated). b) nGO (copolymer). c) nGO (co-polymer and folic 
acid). Effect of surface functionalization (Cop and Cop-FA) on the quantum efficiency of 
an nGO. d) Improvement in the quantum efficiency of a coated nGO (Cop and Cop-FA) 
over an uncoated nGO. The emission maxima were seen to red-shift in the following way: 
PLmax (nGO) = 489 nm, PLmax (nGO-Cop) = 497 nm, PLmax(nGO-Cop-FA) = 504 nm. e)  
It was critical to evaluate the quantum efficiency with or without organic surface 
functionalization. Surface functionalized nGOs (PEG-PEI) co-polymer, nGOs 
(PEG-PEI-FA) exhibited improved quantum efficiency over non-coated nGOs 
under similar conditions (Figure. 12d).  
Table 5. Determination of the quantum yield for coated and non-coated nGOs. The 
quantum yields for nGO, nGO-Cop, nGO-Cop-FA were 4.8%, 6.2% and 7.1% respectively. 
Parameters nGO nGO-Cop nGO-Cop-FA 
Concentration 0.01 mg/ml 0.01 mg/ml 0.01 mg/ml 
Quantum yield 4.8 % 6.2 % 7.1 % 
F0 (λexc=405 nm)/maxPL 15.8 / 493 nm 16.1 / 498 nm 17 / 501 nm 
F0 (λexc=488 nm)/maxPL 5.3 / 527 nm 7.7 / 528 nm 8.7 / 528 nm 
F0 (λexc=532 nm) /maxPL 3.2 / 588 nm 5.4 / 589 nm 7.6 / 590 nm 
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Consequently, organic functionalization enhances quantum efficiencies along with 
providing better colloidal stability and presumably plays an important role in cellular 
applications, as discussed previously. 
The cell viability of each separate surface modification using different concentrations 
of nGO nanoparticles with HeLa cancer cells was thus evaluated.  
 
Figure 13. Demonstration of the biocompatibility of nGOs for cellular applications. A 
WST-1 cell viability assay was performed by increasing the concentration of the nGO 
particles with different surface functionalizations 10-fold. The final cell population in each 
treatment was directly proportional to the absorbance values. Negative control cells were 
untreated and positive control cells were treated with 5 μM staurosporine (toxin), a known 
inhibitor of kinases. The cell viability was observed to be high, even at nGO concentrations 
of up to 100 μg/ml. Error bars represent standard deviation. 
The viability cells incubated with nGO particles with different surface 
functionalization exhibited similar cellular viability in comparison to negative 
control cells. The viability of the nGO-incubated cells was observed to be very high 
in comparison to cells treated with Staurosporine (a toxin) after 48h. Consequently, 
we concluded that there was no visible cytotoxicity observed with nGOs or their 
surface functionalized derivatives (Figure. 13). The biocompatibility evaluation 
showed that nGOs are safe for cellular applications even at higher concentrations 
(100 μg/ml).  
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The optical detectability of nGOs (surface coated and uncoated) for cell labeling was 
compared and evaluated by confocal microscopy. We observed bright PL from 
surface-coated nGOs (PEG-PEI-FA) as compared to uncoated nGOs (Figure. 14a-
f). The PL was detected throughout the cytoplasmic space, thus suggesting that the 
nGO particles were efficiently internalized by the cells. The nGO particles seemed to 
be compartmentalized in endosomes after endocytosis and formed intracellular 
aggregates of detectable sizes. In addition to the added benefits of improving the 
quantum efficiency (Figure. 14), PEG-PEI co-polymers presumably facilitate 
cellular uptake134,193,194 of nGOs. Since nGOs are negatively charged particles, the 
electrostatic adsorption of PEI contributes to the overall positive charge on the nGO 
surface, while the PEG part promotes the colloidal stability by steric stabilization 
under aqueous conditions195. The positive charge and colloidal stability of the nGOs 
improves their cellular uptake by promoting interactions with the negatively charged 
membranes of cells (Paper IV).  
 
Figure 14. Effect of surface coating with PEG-PEI polymers with affinity ligands (Folic acid-
FA) on cellular labeling for bioimaging.  a) Hoechst stained nuclei of HeLa cells. b) PL from 
nGO (uncoated). c) Overlay. Surface coating promotes cellular uptake and enhances 
quantum efficiency thus improving the detectability of nGOs in cells. d) Hoechst stained 
nuclei of HeLa cells. e) Improved PL from coated nGOs in cells. f) Overlay. g) ImageJ based 
quantitative intracellular intensity analysis for nGOs (uncoated) and surface coated nGOs. 
Error bars represent standard deviation. 
Furthermore, quantitative analysis of cellular uptake was performed with ImageJ by 
calculating the intracellular intensity of the signal (Figure. 14g). Cell samples with 
both nGOs and nGOs (coated) were imaged with a confocal microscope using the 
same setting for quantitative comparison. The intracellular intensity analysis 
suggested that the uptake of the coated nGOs was improved by almost 100% 
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compared to uncoated ones. Therefore, the overall results suggest that the surface 
functionalization of nGOs significantly improves their PL and cellular 
internalization. 
5.1.6 Evaluation of optical probes for cell tracking over an in vivo CAM model 
The ex-ova version of the chicken chorioallantoic membrane model (CAM)182,196,197 
was selected as an animal model for in vivo imaging (Paper IV & VI ).  
Table 6. Nanomaterials with surface functionalization and their applications for in vivo 
imaging. 
Nanomaterials 
studied for in vivo 
imaging 
Surface functionalization Application 
nGO-Cop-FA Coated with PEG-PEI (Co-polymer) 
and attached with affinity ligand FA 
(Folic acid). 
In vivo imaging of 
labeled cancer cells 
MSN-Cop-FA Coated with PEG-PEI (Co-polymer) 
and attached with affinity ligand FA 
(Folic acid). 
In vivo imaging  
 
The ex-ova (shell less) version of the CAM (chorioallantoic membrane) model 
provided an optically transparent in vivo model with a large surface area and ease of 
tumor implantation (Figure. 15a). Therefore, the non-invasive in vivo imaging of 
cancer cells labeled with nGO-Cop-FA particles was performed to demonstrate the 
potential of nGO as a stable optical probe (Table. 6). The ex-ova model offered easy 
access to microvasculature and easy implantation of nGO-Cop-FA labeled tumor 
cells (Figure. 15b).  
The shell of the fertilized egg was carefully removed and its contents were placed in 
a weighing boat (Figure. 15a).  Cancer cells with functionalized nGOs, as a PL 
marker were implanted over the CAM (Figure. 15b). The nGO labeled cancer cells 
were allowed to grow for one week to form tumors (Figure. 15c). The nGO labeled 
cancer cells (HeLa, A549, and MDA-MB-231) (Figure. 15d-f) were bright and 
detectable, even after 1 week of cell implantation. The nGO labeling allowed the 
detection of implanted cells, with a low laser power, without any noticeable damage 
to cells or vasculature.  
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Figure 15. Surface functionalized and affinity ligand attached nGOs (PEG-PEI-FA) as an 
optical probe for in vivo imaging. a) Ex ova (shell less) CAM model. The large surface area 
with plenty of vasculature allows implantation of cancer cells. b) Implantation of cancer 
cells over the ex-ova CAM model. c) nGO labeled tumor. Multi-photon microscopy allows 
imaging of nGO labeled tumors after 1 week of implantation (arrow). d) HeLa cells. e) 
A549 cells. f) MDA-MB-231 cells. The two-photon imaging parameters were MP Ex. 
800nm, Nondescanned detector Em.430-480nm, 20X dip objective.   
Fluorescently labeled MSNs were also evaluated for their in vivo detectability in the 
CAM model (Paper VI). The in vivo imaging of MSNs was performed by injecting 
them into the blood vessels of the chick embryo CAM (Figure. 16). MSNs were 
surface coated with the PEG-PEI copolymer, and the affinity ligand FA was 
attached to them (Table.6). Further, MSNs were conjugated with the fluorophore 
rhodamine.  
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Figure 16. In vivo imaging of circulating MSN nanoparticles coated with a copolymer, and 
with an attached affinity ligand, folic acid (FA) in blood vessels of the chicken embryo. a) 
blood vessel (FITC dextran labeled). b) Nuclei (Hoechst labeled nuclei). c) Detection of 
circulating MSN-Cop-FA nanoparticles in blood vessels. d) Overlay image.    
The CAM model provided the technical simplicity needed to understand the 
biological behavior of MSN in an in vivo environment and the optically transparency 
allowed imaging (two-photon excitation) inside blood vessels (Figure. 16). The 
MSN-Cop-FA nanoparticles were detectable, bright and stable under in vivo 
conditions. The MSN-Cop-FA‘s detectability and stability make it a potential 
candidate for the targeted and monitored intravenous delivery of drugs (Paper VI).  
5.2 Drug / siRNA delivery II 
5.2.1 Nanodiamond-silica composites as potential multifunctional probes 
Having established the cellular imaging capability, cytocompatibility, cellular 
trafficking and morphological characteristics of NDs, as described above, we were 
interested in loading the NDs with drugs to test their broader applicability (Paper I). 
We fabricated a novel core-shell composite material using NDs as the fluorescent 
core and mesoporous silica as the outer shell (ND@MSN)20. NDs offer a limited 
surface area for delivery i.e. only the external surface area can be exploited for drug 
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adsorption. Mesoporous silica is a well-established versatile material for the delivery 
of drugs19,137. A mesoporous silica shell provides a large surface to volume ratio, 
allows the attachment of targeting moieties and functional organic groups; which 
can be further exploited for surface functionalization and a higher degree of cargo 
loading for drug-delivery applications115,180. Moreover, the photoluminescence 
originating from the ND core allows it to be subsequently imaged with cells. 
Therefore, the ND@MSN could be exploited as a potential multifunctional probe for 
drug-delivery and imaging (Paper I).  
Table 7. ND@MSN with surface functionalization. 
Nanomaterial for 
drug-delivery 
Surface functionalization 
ND@MSN Core-shell composite of nanodiamond (core) with silica 
shell. 
ND@MSN-Cop Core-shell nanodiamonds silica composite surface 
functionalized with PEG-PEI Co-polymer coated 
 
Coating NDs with a silica shell also provided a regular shape and helped minimize 
aggregation. TEM imaging of the novel composites revealed the ordered pores of the 
silica and the ND localized in the core (Figure. 17a). We investigated the 
comparative drug loading capacity for NDs, ND@MSN composites, and ND@MSN-
Cop. The dye DiI, a lipophilic, plasma membrane non-permeable hydrophobic 
molecule, was selected as the cargo molecule to study the drug loading capacity of 
the composites and the subsequent intracellular release of the dye. Thus, the 
designed delivery system could also facilitate the intracellular delivery of poorly 
water-soluble drugs, especially non-lipophilic compounds that show low 
permeability into biological membranes. However, the delivery system could also be 
used as a carrier for liquid or semisolid forms of lipophilic drugs, also for purposes 
other than intracellular delivery198. The dye adsorption study concluded, that full 
adsorption of the DiI dye (2.5wt %) was observed with hybrid composites, whereas 
with NDs an absorbtio of only 0.5wt% was reached60. Some non-significant leaching 
of the DiI dye was observed with all samples during co-polymer coating, which was 
conducted under aqueous conditions. Hence, coating NDs with silica vastly 
improves their drug loading capability. 
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Figure 17. Characterization of the morphology and PL properties of ND@MSN (hybrid 
composites). a) High-resolution TEM imaging of ND@MSN. The ordered pores of the 
mesoporous silica shell can be seen with the ND as the core. b) Silica coating over NDs had 
no adverse effects on the PL properties of NDs.  Zero-phonon lines of NVo (neutrally 
charged) and NV- (negatively charged) optical centers are shown by arrows at 576 nm, and 
639 nm, respectively.  
We performed a PL spectra analysis of NDs and ND@MSN at a 488 nm laser 
excitation. The observations suggest that there are no adverse effects on the PL 
properties of NDs due to the silica coating (ND@MSN). On relative terms, the 
increase in photoluminescence appears to be more than ‘slight’ (Figure. 17b). 
ND@MSN-PEI-PEG were expected to promote the efficient delivery of loaded cargo 
along with maximizing delivery to a population of cells. The obtained results suggest 
that ND@MSN-PEI-PEG could successfully permeate across the cell membrane, 
without showing any particle aggregation, and no premature release of content 
(Figure. 18a). On the contrary, ND@MSN tended to form large aggregates and were 
not able to cross the plasma membrane, thus leading to unsuccessful delivery of 
hydrophobic model drugs (Figure. 18b). The observed results imply the importance 
of surface functionalization of ND-based carriers for drug delivery and cellular 
internalization (Paper I). 
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Figure 18. Intracellular drug delivery by ND@MSN and effects of surface functionalization 
(co-polymer) for delivering the hydrophobic model drug. A co-polymer (PEI-PEG) coating 
over ND@MSN facilitates cellular uptake, prevents premature release of cargo and prevents 
aggregation of hydrophobic drugs. a) Successful internalization of DiI loaded ND@MSN. b) 
Aggregation of uncoated ND@MSN. The intracellular release of DiI and subsequent imaging 
with the multifunctional ND@MSN@PEI-PEG. c) A bright field image of d&e. d) PL 
originating from ND cores, suggests endosomal localization, e) while the release of DiI 
observed throughout the cytoplasm suggests endosomal escape of the cargo. f) The co-
localization of the ND signal with DiI indicates the successful intracellular release of DiI.         
Upon the successful internalization of ND@MSN-PEI-PEG, significant amounts of 
intracellular release of cargo were observed in the cells (Figure. 18c). NDs were seen 
localized in an aggregated fashion, suggesting endosomal trapping (Figure. 18d). As can 
be seen, the DiI dye was spread out throughout the cytoplasm (Figure. 18e). The co-
localization of the ND signal with DiI (yellow) is indicative of the successful intracellular 
release of DiI (red) (Figure. 18f). The results suggest that ND@MSN-PEI-PEG could be 
a potential system for the efficient intracellular delivery of poorly water-soluble drugs.  
5.2.2 siRNA delivery 
RNAi using siRNAs is a promising and a highly potent mechanism for selectively 
inhibiting specific genes37,40. However, it is challenging to protect the siRNAs from 
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degradation and to deliver siRNAs in a sustained manner for long term gene-based 
therapy40,199. Therefore, we developed and evaluated an MSN (MSN-PEI-linker-PEI) 
based nanocarrier, in which hyperbranched polycations (PEI) were conjugated with 
intracellularly cleavable bonds for the long term sustainable release of siRNA 
(Figure. 19) (Paper V). 
 
Figure 19. Schematic representation of the design of MSN nanocarriers (a) MSN pores were 
conjugated with the PEI polymer. a) Functional COOH groups were further attached to 
the PEI polymers. Further, intracellularly cleavable disulfide bonds (Linkers) were 
chemically attached. (b) Representation of siRNA loading.  Negatively charged siRNAs 
were electrostatically attached to the positively charged, exterior PEI. 
The cellular viability of MSN nanocarriers (without siRNA) was evaluated by the 
WST-1 assay. The results of the WST-1 assay showed that the viability of MDA-MB-
231 cells incubated with the MSN nanocarriers incubated for 72h remained 
comparable to negative control cells and that no significant toxicity was observed 
with the MSN nanocarriers (MSN-PEI-linker-PEI). The results for lower MSN 
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nanocarrier concentrations (2 and 10 μg mL-1) suggest that the viability was almost 
similar to negative control cells (Figure. 19).  
 
Figure 20. In vitro cell viability of MSN nanocarriers (MSN-PEI-linker-PEI) performed 
with WST-1 cell proliferation assay. Error bars represent standard deviation. 
However, it is well established that a higher concentration of PEI could cause 
toxicity200,201. The WST-1 assay suggests that there was minimal toxicity associated 
with MSN nanocarriers at a higher concentration (50 μg mL-1). However, to avoid 
any toxic effects on cells, consequently, any further biological evaluations were 
carried out at a concentration lower than or equal to 20 μg mL-1 (Paper V). 
The uptake of MSN nanocarriers was evaluated using MDA-MB-231 cells. FITC-
labeled MSN nanocarriers (20 μg mL-1) were incubated for 24h and 48h. Confocal 
microscopy was applied to qualitatively analyze the uptake efficacy. The MSN 
nanocarriers were observed to be widely spread throughout the cytoplasmic space 
and the fluorescence signal from MSN nanocarriers was observed to come from be 
aggregated foci (Figure. 21). The fluorescence signal from MSN nanocarriers 
suggests that most of the particles were internalized within the first 24h (Figure. 21c-
e). There was no significant increase observed in the fluorescence signal in cells 48h 
after the internalization of the MSN nanocarriers (Figure. 21h-j). 
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Figure 21. Internalization efficacy of MSN nanocarriers in MDA-MB-231 cells. a-e) uptake 
after 24 h of incubation. f-j) uptake after 48 h.  
To evaluate and validate the newly designed MSN nanocarriers, we performed a 
long-term release study (96h) with live cell confocal microscopy (Figure. 22). MSN 
nanocarriers were conjugated with FITC (green) and loaded with fluorescent siRNAs 
(Alexa-555 labeled siRNA), as a transfection control for slow and sustained release. 
Furthermore, the release of siRNAs from the MSN nanocarriers was quantified with 
the Volocity colocalization software based on Pearson’s colocalization coefficient. 
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Figure 22. Slow and sustained intracellular release of siRNAs from MSN nanocarriers. We 
observed the progressive and sustained release of siRNAs (Alexa 555 labeled- red) from the 
pores of the MSN nanocarriers (FITC labelled-green). The intracellular release of siRNAs 
from MSN nanocarriers and the co-localization of the Alexa 555 and FITC signals over 
time at a) 0-2 h, b) 24 h, c) 48 h, d) 72 h and e-f) 96 h. The intracellular release of siRNA 
demonstrated that the fluorescence signals from the siRNA and MSN nanocarriers were 
mainly separated at 96 h. Thus indicating the slow and sustained release of siRNA into the 
intracellular space from the mesopores of MSN nanocarriers. 
The initial observation at 0-2h shows the cellular internalization of MSN. We 
observed co-localized yellow fluorescent signals from the MSN nanocarriers (green) 
loaded with siRNA (red) (Figure. 22a, 23). The co-localized signal suggests that no 
premature release of siRNA was observed from the MSN nanocarriers. The co-
localization at 24h, suggests that the MSN nanocarriers (with siRNA) were mostly 
intact and had not yet released their siRNA (Figure. 22b). However, we observed the 
gradual increase (48h onwards) in distinct red fluorescence over time in the 
cytoplasm and the degree of co-localization was progressively lower at each 
successive time point (Figure. 22c-f, 23). Furthermore, a significant increase was 
observed in the green fluorescence, suggesting the partial release of the siRNA from 
the MSN nanocarriers (Figure. 22c-f).  However, at 72h, live cell imaging suggested 
that some MSN nanocarriers still co-localized with siRNA in the cells. This might be 
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interpreted as the persistent and slow release of siRNA from the mesopores (Figure. 
22d).  
 
Figure 23. The degree of co-localization was quantified by calculating Pearson’s correlation 
coefficient. The co-localization of the MSN nanocarriers and the siRNA fluorescence signal 
was observed to gradually decrease over time (0-96h), suggesting the sustained release of 
siRNA from the mesopores of the MSN nanocarriers. Error bars represent standard 
deviation. 
Live cell imaging at 96h (Figure. 22f) shows well-separated fluorescence signals from 
the MSN nanocarriers (green) and the siRNA (red). siRNA release was observed to 
be more diffused as compared to the localized signal from the MSN nanocarriers. It 
was also observed that not all cells or all MSN nanocarriers exhibited synchronized 
release of the siRNA. Some cells exhibited more efficient release of siRNA than other 
cells. Based on the results above, it can be concluded that the MSN nanocarriers were 
efficient in delivering the siRNA intracellularly in a slow and sustained manner over 
a period of 96h, while protecting the siRNA from intracellular degradation for long 
term delivery (Figure. 22). 
The above siRNA release analysis with live cells suggested that 72-96h could be an 
optimal time for the efficient release of siRNA from our MSN nanocarriers. 
Therefore, to evaluate the gene knockdown efficacy of the MSN nanocarriers, 100-
120h should be the ideal timeframe for achieving significant gene knockdown. To 
validate the transfection efficiency of the MSN nanocarriers, we used the commercial 
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AllStars Hs Cell Death Control siRNA, (Qiagen). The selected commercial siRNA 
was a blend of potent siRNAs, involved in the targeting of genes vital for cell 
survival175,202. The transfection efficacy of MSN nanocarriers was compared to a 
commercial transfection agent, Lipofectamine RNAiMax. It has an excellent 
transfection efficacy and is routinely used as an in vitro transfection agent.  
 
Figure 24. Gene knockdown efficiency of MSN nanocarriers evaluated by 1) Monitoring 
the growth of live cells 2) crystal violet staining and 3) WST-1 assay. Negative control cells 
were untreated and were observed to be confluent after 120h. Positive control cells were 
treated with staurosporine (cell growth inhibitor) and cells were mostly observed to be dead 
after 120h. MSN nanocarriers were found to be efficient in knocking down genes, as the 
inhibition of cell growth was observed. Lipofectamine RNAiMax served as a positive 
transfection control.  a) Cell growth after 120h, MSN nanocarriers loaded with the AllStars 
Hs Cell Death Control siRNA. Live images with each treatment after 120 h (Figure 19a (a-
d)). b) Cell viability as assessed by crystal-violet staining of cells at 120h.  c) Cell viability 
assessed by the WST-1 assay after 120 h. Error bars represent standard deviation.  
The RNAi functionality of MSN nanocarriers was experimentally evaluated by 
complementary techniques for determining cell viability 1) long term growth 
monitoring by IncuCyte ZOOM®, 2) crystal violet staining and 3) a biochemical assay 
(WST-1 assay). The evaluation with different techniques demonstrated that the MSN 
nanocarriers were efficient in delivering siRNA vehicles for gene knockdown 
(Figure. 24). The experimental results can be summarized 1) nanocarriers have a 
demonstrated efficient protective effect on the loaded siRNA; 2) internalization is 
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followed by the endosomal escape of the siRNA; 3) the siRNA  is released 
intracellularly in a sustained manner. Consequently, the developed MSN nanocarrier 
system includes the desired characteristics of a suitable vehicle for the in vivo delivery 
of siRNA. In summary, this study may bring a new outlook for designing vehicles for 
siRNA delivery and promote the understanding of host-cargo interactions for the 
further application of porous nanomaterials for the long-term delivery of siRNA 
(Paper V).  
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6 Conclusion and outlook 
In this thesis, the suitability of fluorescent carbon-based nanoparticles 
(nanodiamonds and nanographene oxide), mesoporous silica nanoparticles and 
nanodiamond- silica composites, and their different surface modifications, were 
evaluated for applications in cancer cell imaging and drug / siRNA delivery.  
Cancer cells were imaged with different in vitro and in vivo fluorescence microscopy 
techniques. Carbon-based fluorescent nanomaterials (NDs and nGO) can be 
efficiently applied for cell imaging as alternatives to organic fluorophores. They were 
shown to be non-toxic for cell labeling in our studies (PAPER I, IV). The intracellular 
trafficking studies of NDs suggested that cells manage the non-biodegradable 
material by continuous endocytosis and exocytosis. This provides additional 
information about the interaction of cells with nondegradable materials (PAPER II). 
Novel applications of NDs as CLEM labels promise to open up new opportunities 
for using the material in integrating advanced imaging systems such as electron 
microscopy and super resolution microscopy (PAPER III). In general, NDs are 
bright, electron dense, photostable and compatible with STED microscopy for cell 
labeling (PAPER I-III).  
nGOs have shown to be efficient, stable and multi-color optical markers for cancer 
cell labeling. The results obtained in this study demonstrate the potential of nGOs as 
non-invasive in vivo optical imaging probes for the long term tracking of tumors in 
a model organism (PAPER IV). The nGOs have similar optical properties as 
quantum dots, however, their non-toxic nature brings added advantages for the 
long-term observation of cancer cell.   
Surface modifications of nanoparticles possess great advantages for cellular imaging 
and drug delivery applications. In our studies, surface functionalization with PEG-
PEI polymers and the attachment of an affinity ligand (folic acid) were shown to 
facilitate optical imaging and drug delivery. Surface functionalized NDs and nGOs 
showed higher cellular uptake and detectability than their non-modified 
counterparts (PAPER I & IV). In the case of nGOs, improved luminescence quantum 
efficiencies were observed with PEG-PEI-FA coating over uncoated nGOs (PAPER 
IV). The reason for the increase in quantum efficiency needs to be further 
investigated.    
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For drug delivery applications, the evaluated multifunctional composite 
(ND@MSN) with a PEI-PEG surface functionalization enabled cell imaging and the 
intracellular delivery of a poorly water-soluble model drug. The study emphasizes 
the application of dual purpose polymers (positively charged PEI and PEG for 
colloidal stability) for facilitating the delivery of hydrophobic drugs. The results 
obtained with a composite molecule with dual imaging and drug delivery properties 
represent a novel contribution to the development of multi-functional probes 
(PAPER I).   
The delivery of siRNAs into cells remains challenging for many reasons. An ideal in 
vivo delivery system should offer advantages such as slow, sustained long-term 
intracellular delivery for an efficient knockdown. The presented MSN nanocarrier 
system has the potential of overcoming the main barriers associated with the delivery 
of siRNA. The developed system incorporates the positively charged hyperbranched 
PEI with intracellularly cleavable disulfide bonds (Paper V). The results can be 
concluded as follows: the newly developed MSN nanocarriers were internalized 
efficiently, they were biologically compatible and they performed the slow and 
sustained intracellular release of the siRNA for a prolonged time, while protecting 
the siRNA from degradation. Further, MSN nanocarriers can be applied to in vivo 
delivery, which is not possible with current commercial in vitro transfection agents. 
The MSN nanocarrier system showed an overall promising knockdown efficiency, 
which will prospectively empower more effective in vivo gene knockdown strategies 
for improved mRNA silencing by RNAi (Paper V).   
The results presented in the thesis contribute new knowledge for the development of 
improved strategies for cancer cell imaging and drug-delivery. The role and effects 
of organic surface functionalization approaches have been broadly discussed in 
cancer cell imaging. The developed drug /siRNA delivery systems provide a glimpse 
of some solutions for the increasingly complex and challenging field of cancer 
drug/siRNA delivery systems. However, many aspects of cell imaging and the 
delivery system remain to be investigated before translational clinical applications 
can be designed.  
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